Notably, we found that NSCLC patients in the low-risk group had significantly better prognosis than those in the high-risk group after receiving anti-PD-1/PD-L1 therapy (GSE135222, Figure 5A). Here, PDCD1 is linked to non-small cell lung carcinoma.